Manufacturing News of Note—Pact Pharma snags Kite's Tim Moore; Catalent, Minerva hook up


> South San Francisco-based Pact Pharma has enticed Tim Moore from Gilead's Kite Pharma to serve as Pact's president and chief technical officer as it develops TCR-T cell therapies for the eradication of solid tumors. Release 

> Catalent and clinical-stage biotech Minerva Neurosciences have struck a deal for the CDMO to manufacture and package the finished dose form of roluperidone (MIN-101), Minerva’s investigational compound for the treatment of symptoms of schizophrenia. Release 

> Cellectis, a Swiss biotech working on immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), has reached an agreement for Lonza to handle clinical manufacturing. Release


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Novasep has launched Senefill, a unit dedicated to fill-and-finish aseptic commercial operations. It is in Seneffe, Belgium. Release

> Nanoform will conduct an evaluation of its nanoparticle technology across a range of AstraZeneca’s pharmaceutical products. Release

> CapsCanada, which makes vegetarian K-CAPS, is moving its headquarters to a facility in Dania Beach, Florida. Release 



Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.